Nektar Therapeutics (NKTR) Income from Continuing Operations (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Income from Continuing Operations of 43154000.0 for Q1 2026, up 7.04% year-over-year from 40316612.34 in Q1 2025, and down 11079.79% quarter-over-quarter from 386000.0 in Q4 2025.
Nektar Therapeutics (NKTR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 43154000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 7.04% year-over-year to 43154000.0; the TTM figure through Mar 2026 stood at 117735000.0 (down 13.44% YoY), while the FY2025 annual figure was 121002000.0, down 28.5% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 43154000.0, down from 386000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 32054000.0 in Q4 2024, with the low at 159068000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 43154000.0 (2026), against an average of 48395058.82.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations slumped 308.58% in 2023, then soared 176.18% in 2024.
- Nektar Therapeutics' Income from Continuing Operations stood at 20174000.0 in 2022, then plunged by 308.58% to 42079000.0 in 2023, then soared by 176.18% to 32054000.0 in 2024, then tumbled by 101.2% to 386000.0 in 2025, then plunged by 11079.79% to 43154000.0 in 2026.
- Business Quant data shows NKTR's Income from Continuing Operations at 43154000.0 in Q1 2026, 386000.0 in Q4 2025, and 34988000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -43.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.15 Mn |
| Dec 31, 2025 | -386,000.00 |
| Sep 30, 2025 | -34.99 Mn |
| Jun 30, 2025 | -39.21 Mn |
| Mar 31, 2025 | -46.42 Mn |
| Dec 31, 2024 | 32.05 Mn |
| Sep 30, 2024 | -37.06 Mn |
| Jun 30, 2024 | -52.36 Mn |
| Mar 31, 2024 | -36.80 Mn |
| Dec 31, 2023 | -42.08 Mn |
| Sep 30, 2023 | -45.84 Mn |
| Jun 30, 2023 | -51.12 Mn |
| Mar 31, 2023 | -137.02 Mn |
| Dec 31, 2022 | 20.17 Mn |
| Sep 30, 2022 | -59.05 Mn |
| Jun 30, 2022 | -159.07 Mn |
| Mar 31, 2022 | -90.39 Mn |
| Dec 31, 2021 | 378.80 Mn |
| Sep 30, 2021 | -129.71 Mn |
| Jun 30, 2021 | -125.52 Mn |